First FDA-approved treatment for primary membranous nephropathy

Image: Envato

Genentech, a member of the Roche Group, has announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria.

Gazyva becomes the first and only therapy to receive FDA approval for this disease, having previously been granted Breakthrough Therapy Designation. A chronic autoimmune disease that can lead to kidney failure, pMN carries a substantial human and economic burden for patients, caregivers and health systems alike. Proteinuria is a key indicator of kidney damage characterised by high urine protein levels.

“The FDA approval of Gazyva represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease,” said Levi Garraway, chief medical officer and head of global product development.

“With Gazyva, we are turning decades of specialised antibody engineering into tangible outcomes for patients with immune-mediated kidney diseases. By achieving significantly higher complete remission rates compared to tacrolimus, Gazyva offers a more effective approach to help achieve durable disease control.”

The approval is based on positive results from the Phase III MAJESTY study. The trial met its primary endpoint, with 36.1% of adults achieving complete remission (CR) of proteinuria at two years (104 weeks) with Gazyva versus 5.7% with tacrolimus. Key secondary endpoints showed Gazyva was superior to tacrolimus in achieving overall remission (complete or partial remission) at week 104 and complete remission at week 76. Safety was in line with the well-characterised profile of Gazyva and no new safety signals were identified. MAJESTY data were featured at the 63rd European Renal Association (ERA) Congress in June 2026 as a late-breaking oral presentation and published in the New England Journal of Medicine (NEJM). Data are also being submitted to other global health authorities, including the European Medicines Agency.

“People living with primary membranous nephropathy face the risk of progressive kidney damage and significant uncertainty about their health,” said Marc Hurlbert, CEO of the National Kidney Foundation.

“The first FDA approval of a treatment specifically for this condition is a milestone, finally giving patients and clinicians more treatment options. Our hope is that the approval of Gazyva provides a turning point for people navigating pMN.”

pMN is a rare, chronic autoimmune condition that causes potentially irreversible kidney damage and can lead to kidney failure. People living with pMN often experience fatigue, oedema (swelling) and significant emotional and social challenges that deeply affect both patients and their families. Beyond the individual impact, pMN places a burden on healthcare systems. Achieving complete remission is important to help maintain kidney function and delay or prevent the onset of serious and potentially fatal complications.

“pMN can lead to debilitating physical and psychological symptoms that place a heavy burden on patients, families and healthcare systems alike,” said Teresa Graham, CEO of Roche Pharmaceuticals.

“This first-ever FDA approval delivers an important targeted treatment option for the pMN community and expands how many people may benefit from Gazyva across multiple severe immune-mediated kidney diseases.”

This is the third FDA approval of Gazyva in immune-mediated kidney diseases, following approvals in idiopathic nephrotic syndrome (INS) and lupus nephritis (LN). The FDA is currently evaluating Gazyva for adults with systemic lupus erythematosus (SLE) and is expected to make a decision by December 2026.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recently issued a positive opinion recommending the approval of Gazyva for adults with SLE, with a final decision from the European Commission expected in the near future.